The dosage of Praluent for pediatric patients aged 8 years and older with HeFH is based on body weight and can be adjusted based on LDL-C lowering response. The Food and Drug Administration (FDA) has ...
The Food and Drug Administration on Tuesday approved a once-monthly dose form of the cholesterol drug Praluent. The drug, co-developed by Regeneron Pharmaceuticals and Sanofi, first earned FDA ...
TARRYTOWN, N.Y., March 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the U.S. Food & Drug Administration (FDA) has extended the approval of Praluent ® ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback